1 Bordea MA, Costache C, Grama A, et al. Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome[J]. Physiol Res, 2022, 71(1): 17-27. PMID: 35043641. PMCID: PMC8997683. DOI: 10.33549/physiolres.934672.
2 Yeung RS. Kawasaki disease: update on pathogenesis[J]. Curr Opin Rheumatol, 2010, 22(5): 551-560. PMID: 20616737. DOI: 10.1097/BOR.0b013e32833cf051.
3 Turnier JL, Anderson MS, Heizer HR, et al. Concurrent respiratory viruses and Kawasaki disease[J]. Pediatrics, 2015, 136(3): e609-e614. PMID: 26304824. DOI: 10.1542/peds.2015-0950.
4 Bustos BR, Jaramillo-Bustamante JC, Vasquez-Hoyos P, et al. Pediatric inflammatory multisystem syndrome associated with SARS-CoV-2: a case series quantitative systematic review[J]. Pediatr Emerg Care, 2021, 37(1): 44-47. PMID: 33181794. PMCID: PMC7780931. DOI: 10.1097/PEC.0000000000002306.
5 Belayneh DK, Calais F. Asymptomatic giant right coronary artery aneurysm in Kawasaki disease: a case report[J]. Clin Case Rep, 2020, 8(12): 2732-2738. PMID: 33363814. PMCID: PMC7752556. DOI: 10.1002/ccr3.3259.
6 Santos BSD, Santos FSD, Ribeiro ER. Clinical-epidemiological relation between SARS-COV-2 and Kawasaki disease: an integrative literature[J]. Rev Paul Pediatr, 2021, 39: e2020217. PMID: 32876096. PMCID: PMC7461695. DOI: 10.1590/1984-0462/2021/39/2020217.
7 Abrams JY, Weintraub ES, Baggs JM, et al. Childhood vaccines and Kawasaki disease, vaccine safety datalink, 1996-2006[J]. Vaccine, 2015, 33(2): 382-387. PMID: 25444786. DOI: 10.1016/j.vaccine.2014.10.044.
8 Alphonse MP, Duong TT, Shumitzu C, et al. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease[J]. J Immunol, 2016, 197(9): 3481-3489. PMID: 27694492. DOI: 10.4049/jimmunol.1600388.
9 Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019, 19(8): 477-489. PMID: 31036962. PMCID: PMC7807242. DOI: 10.1038/s41577-019-0165-0.
10 Gallizzi R, Corsello G, Pajno GB. Kawasaki disease epidemic: pitfalls[J]. Ital J Pediatr, 2020, 46(1): 121. PMID: 32854742. PMCID: PMC7451231. DOI: 10.1186/s13052-020-00887-4.
11 Ouldali N, Pouletty M, Mariani P, et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis[J]. Lancet Child Adolesc Health, 2020, 4(9): 662-668. PMID: 32622376. PMCID: PMC7332278. DOI: 10.1016/S2352-4642(20)30175-9.
12 Akca UK, Kesici S, Ozsurekci Y, et al. Kawasaki-like disease in children with COVID-19[J]. Rheumatol Int, 2020, 40(12): 2105-2115. PMID: 32936318. PMCID: PMC7492688. DOI: 10.1007/s00296-020-04701-6.
13 Dhanrajani A, Chan M, Pau S, et al. Aspirin dose in Kawasaki disease: the ongoing battle[J]. Arthritis Care Res (Hoboken), 2018, 70(10): 1536-1540. PMID: 29287309. DOI: 10.1002/acr.23504.
14 Ito Y, Matsui T, Abe K, et al. Aspirin dose and treatment outcomes in Kawasaki disease: a historical control study in Japan[J]. Front Pediatr, 2020, 8: 249. PMID: 32478021. PMCID: PMC7241278. DOI: 10.3389/fped.2020.00249.
15 Takeshita S, Kawamura Y, Nakatani K, et al. Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease[J]. Clin Pediatr (Phila), 2005, 44(5): 423-426. PMID: 15965549. DOI: 10.1177/000992280504400507.